| Nome |
# |
|
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena, file e0feeaa9-152a-44d2-e053-6605fe0a8db0
|
132
|
|
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6, file e0feeaa7-f6b4-44d2-e053-6605fe0a8db0
|
129
|
|
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis, file e0feeaa8-497f-44d2-e053-6605fe0a8db0
|
115
|
|
null, file e0feeaa9-5001-44d2-e053-6605fe0a8db0
|
107
|
|
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research, file e0feeaaa-249a-44d2-e053-6605fe0a8db0
|
101
|
|
Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?, file e0feeaa8-1fd0-44d2-e053-6605fe0a8db0
|
98
|
|
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population, file e0feeaa8-ceda-44d2-e053-6605fe0a8db0
|
81
|
|
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes, file e0feeaa9-3dd9-44d2-e053-6605fe0a8db0
|
78
|
|
Immune modulatory effects of novel monoclonal antibodies target therapies in severe eosinophilic asthma patients, file e0feeaa9-2887-44d2-e053-6605fe0a8db0
|
68
|
|
null, file e0feeaaa-1f34-44d2-e053-6605fe0a8db0
|
67
|
|
null, file e0feeaaa-52ef-44d2-e053-6605fe0a8db0
|
63
|
|
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy, file e0feeaaa-1130-44d2-e053-6605fe0a8db0
|
50
|
|
A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists, file e0feeaaa-35c6-44d2-e053-6605fe0a8db0
|
48
|
|
KL-6 in ANCA-Associated Vasculitis Patients with and without ILD: A Machine Learning Approach, file e0feeaab-34f2-44d2-e053-6605fe0a8db0
|
45
|
|
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis, file e0feeaab-e140-44d2-e053-6605fe0a8db0
|
29
|
|
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease, file e0feeaab-da93-44d2-e053-6605fe0a8db0
|
24
|
|
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity, file e0feeaab-0099-44d2-e053-6605fe0a8db0
|
23
|
|
null, file e0feeaaa-063d-44d2-e053-6605fe0a8db0
|
21
|
|
Serial KL-6 measurements in COVID-19 patients, file e0feeaa9-6411-44d2-e053-6605fe0a8db0
|
17
|
|
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study, file e0feeaab-b657-44d2-e053-6605fe0a8db0
|
17
|
|
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males., file e8887f01-8ecd-408c-a6e4-5b1d8e6d5c42
|
16
|
|
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures, file a9aa19de-f7e7-47f4-bd0e-0351d1b2750e
|
15
|
|
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients, file e0feeaab-0e66-44d2-e053-6605fe0a8db0
|
14
|
|
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19, file 96f4df86-86ac-462c-8a12-3ca958289b45
|
13
|
|
Multi-Omics Integrative Approach of Extracellular Vesicles: A Future Challenging Milestone, file ba6e2e89-23fa-45c2-90d2-bafd0ced1dc6
|
12
|
|
null, file 385893c5-b7c4-4d3e-a732-6db17b23ee3f
|
11
|
|
NK and NKT-like cells in granulomatous and fibrotic lung diseases, file e0feeaa8-419c-44d2-e053-6605fe0a8db0
|
11
|
|
PD1, CTLA4 and TIGIT Expression on T and NK Cells in Granulomatous Diseases: Sarcoidosis and ANCA-Associated Vasculitis, file 1ee9d497-3650-41a3-b8b0-9d5031807bdb
|
9
|
|
Clinical and molecular characterization of COVID-19 hospitalized patients, file 125e504f-f9c2-4d04-8ea6-eb60ed7246fe
|
8
|
|
Prevalence of myositis specific and associated antibodies in a cohort of patients affected by idiopathic NSIP and no hint of inflammatory myopathies, file 65e2b7bb-fc24-4727-8ef0-f79ae28df84e
|
8
|
|
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis, file e0feeaa8-11e4-44d2-e053-6605fe0a8db0
|
8
|
|
null, file e0feeaa9-7c6e-44d2-e053-6605fe0a8db0
|
8
|
|
Mapping the human genetic architecture of COVID-19, file e0feeaab-73d3-44d2-e053-6605fe0a8db0
|
8
|
|
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age, file 530676af-72b7-4a15-b48a-51204a80e40d
|
6
|
|
Cytomegalovirus Infection Is Associated with Development of Chronic Lung Allograft Dysfunction, file b7365529-c7fa-4757-b37a-a856cfddac4a
|
6
|
|
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib, file e0feeaa7-e3d8-44d2-e053-6605fe0a8db0
|
6
|
|
null, file e0feeaa8-2038-44d2-e053-6605fe0a8db0
|
6
|
|
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases, file e0feeaa8-6197-44d2-e053-6605fe0a8db0
|
6
|
|
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes, file ebc57d5c-8d48-406c-b361-06dd583c7b6b
|
6
|
|
Whole-genome sequencing reveals host factors underlying critical COVID-19, file b47ac884-9c8d-4cf9-84ab-2c6dfbaa52e5
|
5
|
|
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib, file e0feeaa8-12ef-44d2-e053-6605fe0a8db0
|
5
|
|
Serum amyloid A: A potential biomarker of lung disorders, file e0feeaa8-9bf4-44d2-e053-6605fe0a8db0
|
5
|
|
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males, file 434b66aa-b383-4316-9027-8d28bd50a93f
|
4
|
|
Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence, file 768cdf1a-a36a-43d1-b312-6d89719a3dcb
|
4
|
|
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues, file b27bf0e9-010f-47e6-a116-48649af66e36
|
4
|
|
Serum amyloid A in patients with idiopathic pulmonary fibrosis, file e0feeaa8-11e7-44d2-e053-6605fe0a8db0
|
4
|
|
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis, file e0feeaa8-16fa-44d2-e053-6605fe0a8db0
|
4
|
|
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies, file e0feeaa8-6217-44d2-e053-6605fe0a8db0
|
4
|
|
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features, file e0feeaa8-adec-44d2-e053-6605fe0a8db0
|
4
|
|
Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor, file e0feeaa8-b7fe-44d2-e053-6605fe0a8db0
|
4
|
|
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation, file e0feeaa8-c971-44d2-e053-6605fe0a8db0
|
4
|
|
Serum KL-6 concentrations as a novel biomarker of severe COVID-19, file e0feeaa9-0e1f-44d2-e053-6605fe0a8db0
|
4
|
|
Prognostic bioindicators in severe COVID-19 patients, file e0feeaa9-449f-44d2-e053-6605fe0a8db0
|
4
|
|
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study, file e0feeaa9-5835-44d2-e053-6605fe0a8db0
|
4
|
|
Immunologic responses to antifibrotic treatment in IPF patients, file e0feeaaa-3a6f-44d2-e053-6605fe0a8db0
|
3
|
|
Differential redox proteomic profiles of serum from severe asthma patients after one month of Benralizumab and Mepolizumab treatment, file e0feeaaa-59c5-44d2-e053-6605fe0a8db0
|
3
|
|
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers, file 1b8518ff-3a73-4507-8be4-6eb308bef028
|
2
|
|
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues, file 4b6371f4-5458-443b-941a-cf972c6ace63
|
2
|
|
Oxygen Therapy during Exercise in Patients with Interstitial Lung Diseases, file 595c0671-7c01-456b-92fe-7de9da027917
|
2
|
|
Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a New Protocol for Investigating the Mechanisms of Idiopathic Pulmonary Fibrosis, file 91ec9de9-8671-4cb1-a792-84a2631f79fc
|
2
|
|
An explainable model of host genetic interactions linked to COVID-19 severity, file a40b8f9e-8132-42fb-ba8e-085aaa454eda
|
2
|
|
The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis, file e0feeaa7-ae1d-44d2-e053-6605fe0a8db0
|
2
|
|
Serum amyloid A in patients with idiopathic pulmonary fibrosis, file e0feeaa8-2bc9-44d2-e053-6605fe0a8db0
|
2
|
|
Effects of rituximab therapy on B cell differentiation and depletion, file e0feeaa8-6dd4-44d2-e053-6605fe0a8db0
|
2
|
|
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy, file e0feeaa9-0e1c-44d2-e053-6605fe0a8db0
|
2
|
|
Cytological analysis of bronchoalveolar lavage fluid in asbestos-exposed workers: BALF features in asbestos exposed workers, file e0feeaa9-2d73-44d2-e053-6605fe0a8db0
|
2
|
|
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad, file e0feeaa9-4a30-44d2-e053-6605fe0a8db0
|
2
|
|
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab, file e0feeaa9-4d7d-44d2-e053-6605fe0a8db0
|
2
|
|
Interstitial lung disease associated with psoriatic arthritis: a new disease entity?, file e0feeaa9-75f8-44d2-e053-6605fe0a8db0
|
2
|
|
Clinical phenotyping in sarcoidosis management, file e0feeaaa-2fe7-44d2-e053-6605fe0a8db0
|
2
|
|
Genetic mechanisms of critical illness in COVID-19, file e0feeaaa-50e1-44d2-e053-6605fe0a8db0
|
2
|
|
High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool?, file e0feeaaa-6dac-44d2-e053-6605fe0a8db0
|
2
|
|
Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis, file e0feeaab-3a8a-44d2-e053-6605fe0a8db0
|
2
|
|
Markers of Bronchiolitis Obliterans Syndrome after Lung Transplant: Between Old Knowledge and Future Perspective, file e73530c8-7ca8-43dd-a310-259da1def566
|
2
|
|
AB0611 Neutrophil extracellular traps and interstitial lung disease in ANCA-associated vasculitis: a scoping review, file 88b8a5a6-9db7-4ec4-9d2e-7f8d308b4977
|
1
|
|
Protective Role of a TMPRSS2 Variant on Severe COVID-19 Outcome in Young Males and Elderly Women, file c44a78e1-66be-49a4-a3e1-68030161493b
|
1
|
|
Characterization of NKG2-A/-C, Kir and CD57 on NK Cells Stimulated with pp65 and IE-1 Antigens in Patients Awaiting Lung Transplant, file c88bb55d-8bb0-4f5f-b0af-0d93aa85e5b5
|
1
|
|
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study, file e0feeaa8-b15c-44d2-e053-6605fe0a8db0
|
1
|
|
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases, file e0feeaa9-388a-44d2-e053-6605fe0a8db0
|
1
|
|
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment, file e0feeaa9-388e-44d2-e053-6605fe0a8db0
|
1
|
|
Peripheral biomarkers' panel for severe COVID-19 patients, file e0feeaa9-3a43-44d2-e053-6605fe0a8db0
|
1
|
|
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis, file e0feeaa9-44e9-44d2-e053-6605fe0a8db0
|
1
|
|
Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases, file e0feeaa9-4955-44d2-e053-6605fe0a8db0
|
1
|
|
Serum Amyloid A in lung transplantation, file e0feeaa9-4959-44d2-e053-6605fe0a8db0
|
1
|
|
The role of the combination of echo-HRCT score as a tool to evaluate the presence of pulmonary hypertension in idiopathic pulmonary fibrosis, file e0feeaa9-4d7b-44d2-e053-6605fe0a8db0
|
1
|
|
Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review, file e0feeaa9-5913-44d2-e053-6605fe0a8db0
|
1
|
|
null, file e0feeaa9-62f6-44d2-e053-6605fe0a8db0
|
1
|
|
Integrated approach to bronchoalveolar lavage cytology to distinguish interstitial lung diseases, file e0feeaaa-04b1-44d2-e053-6605fe0a8db0
|
1
|
|
Prognostic role of NK cell percentages in bronchoalveolar lavage from patients with different fibrotic interstitial lung diseases, file e0feeaaa-36b5-44d2-e053-6605fe0a8db0
|
1
|
|
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution, file e0feeaaa-5422-44d2-e053-6605fe0a8db0
|
1
|
|
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease, file e0feeaaa-6529-44d2-e053-6605fe0a8db0
|
1
|
|
The Role of Galectins in Chronic Lung Allograft Dysfunction, file e0feeaaa-6da3-44d2-e053-6605fe0a8db0
|
1
|
|
Extracellular Vesicle Surface Signatures in IPF Patients: A Multiplex Bead-Based Flow Cytometry Approach, file e0feeaaa-6da5-44d2-e053-6605fe0a8db0
|
1
|
|
Prognostic role of KL-6 in SSc-ILD patients with pleuroparenchymal fibroelastosis, file e0feeaaa-6dae-44d2-e053-6605fe0a8db0
|
1
|
|
Strain echocardiography is a promising tool for the prognostic assessment of sarcoidosis, file e0feeaaa-da97-44d2-e053-6605fe0a8db0
|
1
|
|
Extracellular Vesicles in Pulmonary Fibrosis Models and Biological Fluids of Interstitial Lung Disease Patients: A Scoping Review, file e0feeaab-056a-44d2-e053-6605fe0a8db0
|
1
|
| Totale |
1.617 |